FDA Clearance Tracker · P100022
ZILVER PTX DRUG-ELUTING PERIPHERAL STENT
Last checked: Nov 20, 2026Latest source record: Nov 14, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Nov 14, 2012
Approved
Time to decision
894 days
Received Jun 4, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P100022
- Device name
- ZILVER PTX DRUG-ELUTING PERIPHERAL STENT
- Applicant
- Cook Ireland, Ltd.
- Applicant location
- Limerick
- Received
- Jun 4, 2010
- Decided
- Nov 14, 2012
- Decision
- Approved
- Supplements
- 44 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ZILVER PTX DRUG-ELUTING PERIPHERAL STENT. THIS DEVICE IS INDICATED FOR IMPROVING LUMINAL DIAMETER FOR THE TREATMENT OF DE NOVO OR RESTENOTIC SYMPTOMATIC LESIONS IN NATIVE VASCULAR DISEASE OF THE ABOVE-THE-KNEE FEMOROPOPLITEAL ARTERIES HAVING REFERENCE VESSEL DIAMETERS FROM 4 MM TO 9 MM AND TOTAL LESION LENGTHS UP TO 140 MM PER LIMB AND 280 MM PER PATIENT.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code NIU (Stent, superficial femoral artery, drug-eluting).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Cook Ireland, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261274 · Decided Jul 24, 2026 · 98 days after receipt
Device type: Bronchoscope Accessory (KTI) · Otolaryngology (ENT)
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.